Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
Kaiser Permanente
Duke University
Arvinas Inc.
University of Colorado, Denver
City of Hope Medical Center
Eli Lilly and Company
Novartis
Var2 Pharmaceuticals
Takeda
Tempus AI
UNC Lineberger Comprehensive Cancer Center
A2 Biotherapeutics Inc.
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Centre for Research and Technology Hellas
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
Hoffmann-La Roche
Compugen Ltd
Columbia University
Vyriad, Inc.
Intensity Therapeutics, Inc.
Cyprus University of Technology
PureTech
Rutgers, The State University of New Jersey
Universidade Federal de Pernambuco
NextCure, Inc.
Washington University School of Medicine
European Organisation for Research and Treatment of Cancer - EORTC
NantCell, Inc.
Second Affiliated Hospital of Guangzhou Medical University
Washington University School of Medicine
HiberCell, Inc.
Klus Pharma Inc.
Kineta Inc.
Eastern Cooperative Oncology Group
Genzada Pharmaceuticals USA, Inc.
Blue Note Therapeutics
Icahn School of Medicine at Mount Sinai
Roswell Park Cancer Institute
University of Calgary